Prognostic Biomarker TP53 Mutations for Immune Checkpoint Blockade Therapy and Its Association With Tumor Microenvironment of Lung Adenocarcinoma

Prognostic Biomarker TP53 Mutations for Immune Checkpoint Blockade Therapy and Its Association With Tumor Microenvironment of Lung Adenocarcinoma

Immune checkpoint inhibitors (ICIs), is characterized by durable responses and improved survival in non-small cell lung cancer (NSCLC). However, there is a lack of predictive biomarkers to optimize the use of ICIs in cancers. The clinical benefit of patients with lung adenocarcinoma (LUAD) harboring...

Full description

Bibliographic Details
Main Authors: Xinqing Lin, Liqiang Wang, Xiaohong Xie, Yinyin Qin, Zhanhong Xie, Ming Ouyang, Chengzhi Zhou
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-11-01
Series:Frontiers in Molecular Biosciences
Subjects:
TP53
immune checkpoint inhibitors
tumor microenvironment
biomarker
mutation
prognosis
Online Access:https://www.frontiersin.org/articles/10.3389/fmolb.2020.602328/full

Similar Items

Similar Items